Daiichi Sankyo launches Biopten Granules 10% in Japan

29 November 2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has launched natural tetrahydrobiopterin agent Biopten Granules 10% (sapropterin hydrochloride) following the product’s National Health Insurance listing on November 29.

Biopten is a highly pure, chemically synthesized form of natural tetrahydrobiopterin (BH4) that occurs naturally in the human body. It is used to treat patients with atypical hyperphenylalaninemia (HPA) and those with BH4-responsive HPA by maintaining an appropriate phenylalanine level.

Hyperphenylalaninemia is a rare disease with an incidence rate of 1 in 80,000 in Japan. Since mass screening of newborns was started in 1977, a total of 600 have been diagnosed with the condition. Biopten has been designated as an orphan disease drug for its use in treating BH4-responsive HPA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK